U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C12H15NO3.HI
Molecular Weight 349.1648
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROCOTARNINE HYDRIODIDE

SMILES

I.COC1=C2OCOC2=CC3=C1CN(C)CC3

InChI

InChIKey=FYOBFGXHWMNQAJ-UHFFFAOYSA-N
InChI=1S/C12H15NO3.HI/c1-13-4-3-8-5-10-12(16-7-15-10)11(14-2)9(8)6-13;/h5H,3-4,6-7H2,1-2H3;1H

HIDE SMILES / InChI
Molecular Formula HI
Molecular Weight 127.91241
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C12H15NO3
Molecular Weight 221.2524
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Hydrocotarnine is a crystalline alkaloid, obtained from opium and also formed by the reduction of cotarnine. It is a non-narcotic opium alkaloid. Hydrocotarnine is supposed to potentiate the analgesic effect of oxycodone with unknown mechanism.

CNS Activity

CNS Penetrant
2,588

Originator

Topchiev, A.V.
6

Approval Year

Unknown
149,124

Targets

Primary TargetPharmacologyConditionPotency
Cytochrome P450 3A4
127
Inhibitor
8,504
 18.4 µM [IC50]
Cytochrome P450 2D6
62
Inhibitor
8,504
 6.63 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Cancer pain
10
 Primary
Approved
8,583
Unknown

PubMed

Patents

04769480
6
20030039699
8
20090269772
13
7192608
6

Sample Use Guides

In Vivo Use Guide
injections of oxycodone and hydrocotarnine contains 8 mg of oxycodone hydrochloride and 2 mg of hydrocotarnine hydrochloride.
Route of Administration: Other
In Vitro Use Guide
Hydrocotarnine (0.000388–38.8 mM) did not induce a significant change in the metabolic activities of CYP2C9, 2C19, and 2E1. Although weak inhibitory effects were observed on CYP3A4 and 2D6, the inhibition rate was less than 50% at the concentrations below 3.88 mM.
Substance Class Chemical
Record UNII
1U6WI2V74N
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966